The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Effects of the Oral Direct Renin Inhibitor Aliskiren in Patients With Symptomatic Heart Failure
Abstract
Background— Loss of negative feedback inhibition of renin release during chronic treatment with an angiotensin-converting enzyme (ACE) inhibitor leads to a compensatory rise in renin secretion and downstream components of the renin-angiotensin-aldosterone (RAAS) cascade. This may overcome ACE inhibition but should be blocked by a direct renin inhibitor. We studied the effects of adding the direct renin inhibitor aliskiren to an ACE inhibitor in patients with heart failure. Methods and Results— Patients with New York Heart Association class II to IV heart failure, current or past history of hypertension, and plasma brain natriuretic peptide (BNP) concentration >100 pg/mL who had been treated with an ACE inhibitor (or angiotensin receptor blocker) and β-blocker were randomized to 3 months of treatment with placebo (n=146) or aliskiren 150 mg/d (n=156). The primary efficacy outcome was the between-treatment difference in N-terminal pro-BNP (NT-proBNP). Patients’ mean age was 68 years, mean ejection fraction was 31%, and mean�SD systolic blood pressure was 129�17.4 mm Hg. Sixty-two percent of the patients were in New York Heart Association functional class II, and 33% were taking an aldosterone antagonist. Plasma NT-proBNP rose by 762�6123 pg/mL with placebo and fell by 244�2025 pg/mL with aliskiren ( P =0.0106). BNP and urinary (but not plasma) aldosterone were also reduced by aliskiren. Clinically important differences in blood pressure and biochemistry were not seen between aliskiren and placebo. Conclusions— Addition of aliskiren to an ACE inhibitor (or angiotensin receptor blocker) and β-blocker had favorable neurohumoral effects in heart failure and appeared to be well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Self-citationEffects of Enalapril on Mortality in Severe Congestive Heart Failure
The Consensus Trial Study Group* (1987) · New England Journal of Medicine · doi:10.1056/nejm198706043162301 · Cited by 5,121
Swedberg, K., & Kjekshus, J. (1988) · The American Journal of Cardiology · doi:10.1016/s0002-9149(88)80087-0 · Cited by 3,762
A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108
Nagueh, S. F., Middleton, K. J., Kopelen, H. A., Zoghbi, W. A., & Quiñones, M. A. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(97)00344-6 · Cited by 3,029
McMurray, J. J., Östergren, J., Swedberg, K., Granger, C. B., Held, P., Michelson, E. L., Olofsson, B., Yusuf, S., & Pfeffer, M. A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14283-3 · Cited by 2,604
Self-citationPitt, B., Poole-Wilson, P. A., Segal, R., Martinez, F. A., Dickstein, K., Camm, A. J., Konstam, M. A., Riegger, G., Klinger, G. H., Neaton, J., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02213-3 · Cited by 1,961
Self-citationTei, C., Ling, L. H., Hodge, D. O., Bailey, K. R., Oh, J. K., Rodeheffer, R. J., Tajik, A. J., & Seward, J. B. (1995) · PubMed · Cited by 1,547
Nguyen, G., Delarue, F., Burcklé, C., Bouzhir-Sima, L., Giller, T., & Sraer, J. (2002) · Journal of Clinical Investigation · doi:10.1172/jci14276 · Cited by 1,276
Nguyen, G., Delarue, F., Burcklé, C., Bouzhir, L., Giller, T., & Sraer, J.-D. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0214276 · Cited by 1,137
Cited by
Cardiorenal end points in a trial of aliskiren for type 2 diabetes
Parving, H.-H., Brenner, B. M., McMurray, J. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Persson, F., Desai, A. S., Nicolaides, M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208799 · Cited by 1,319
Self-citationPathological Ventricular Remodeling: Mechanisms: Part 1 of 2
Burchfield, J. S., Xie, M., & Hill, J. A. (2013) · Circulation · doi:10.1161/circulationaha.113.001878 · Cited by 766
Parving, H.-H., Brenner, B. M., McMurray, J. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Ghadanfar, M., Weissbach, N., Xiang, Z., et al. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfn721 · Cited by 304
Self-citationSolomon, S. D., Appelbaum, E., Manning, W. J., Verma, A., Berglund, T., Lukashevich, V., Cherif Papst, C., Smith, B. A., & Dahlöf, B. (2009) · Circulation · doi:10.1161/circulationaha.108.826214 · Cited by 301
Self-citationPotassium Homeostasis and Renin-Angiotensin-Aldosterone System Inhibitors
Weir, M. R., & Rolfe, M. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.07821109 · Cited by 265
Metadata
- Authors
- McMurray, J. J. V., Pitt, B., Latini, R., Maggioni, A. P., Solomon, S. D., Keefe, D. L., Ford, J., Verma, A., & Lewsey, J.
- Venue
- Circulation: Heart Failure
- Published
- 2008-05
- Volume
- 1
- Issue
- 1
- Pages
- 17-24
- ISSN
- 1941-3289 (ISSN-L)
- 1941-3297
- OpenAlex
- W1994079702
- Cited by
- 358
- References
- 28
- FWCI
- 39.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of the Oral Direct Renin Inhibitor Aliskiren in Patients With Symptomatic Heart Failure. https://app.cochat.ai/papers/10.1161/circheartfailure.107.740704
- The paper
- McMurray, J. J. V., Pitt, B., Latini, R., Maggioni, A. P., Solomon, S. D., Keefe, D. L., Ford, J., Verma, A., & Lewsey, J. (2008). Effects of the Oral Direct Renin Inhibitor Aliskiren in Patients With Symptomatic Heart Failure. Circulation: Heart Failure. https://doi.org/10.1161/circheartfailure.107.740704
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
